GlassScriptPhysician profile
Misty Dawn Pennington
NPI 1447831730
$6,936.98
in general payments reported to CMS, 2019-2025
33 companies · $945 in 2025
The $945 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,314 · 2022: $1,438 · 2023: $1,864 · 2024: $1,376 · 2025: $945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,120 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,119.79 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $790.18 | 2022-2025 | Watchman Access System, Watchman Flx, Versacross Access Solution |
| Boehringer Ingelheim Pharmaceuticals, INC. | $689.21 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $671.05 | 2021-2025 | Farxiga, Atacand, Andexxa |
| Amgen INC. | $663.64 | 2021-2023 | Repatha |
| Esperion Therapeutics, INC. | $481.94 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $390.35 | 2021-2025 | Verquvo |
| Pfizer INC. | $355.80 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $354.66 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $328.18 | 2021-2024 | Xarelto |
| Novo Nordisk INC | $291.80 | 2021-2024 | Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $291.31 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $197.00 | 2021-2025 | Camzyos |
| Cvrx, INC. | $189.81 | 2022-2025 | Barostim Neo System |
| Kestra Medical Technology Services, INC. | $186.43 | 2025 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $169.41 | 2021-2023 | Onpattro |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $141.08 | 2025 | Uptravi, Opsumit, Opsynvi |
| Amarin Pharma, INC. | $118.41 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $111.39 | 2021-2025 | |
| Abiomed | $81.67 | 2023-2025 | Impella |
| Kiniksa Pharmaceuticals International, Plc | $79.87 | 2024 | Arcalyst |
| Medtronic, INC. | $47.38 | 2022-2024 | Linq II |
| Daiichi Sankyo INC. | $38.34 | 2022-2023 | Injectafer |
| Atricure, INC. | $35.60 | 2023 | |
| Edwards Lifesciences Corporation | $34.50 | 2022 | |
| Lilly USA, LLC | $31.65 | 2022-2025 | Zepbound, Mounjaro |
| Kiniksa Pharmaceuticals, LTD. | $29.19 | 2021 | |
| Impulse Dynamics (USA) INC. | $24.37 | 2023 | Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.46 | 2023 | Lifevest |
| Philips North America LLC | $20.86 | 2024 | (Ck7) Extended Holter |
| Tactile Systems Technology INC | $19.23 | 2025 | Flexitouch Plus, Nimbl |
| Alexion Pharmaceuticals, INC. | $17.61 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $16.32 | 2024 | |
| Csl Behring | $15.28 | 2025 | Kcentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misty Pennington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.